Suchergebnisse - "Hou, Zhiguo"

PubPharm (8)

1

First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE) : a phase 1 study

enthalten in: Signal transduction and targeted therapy | 2024

von Chen, X. | Xu, H. | Chen, X. | +25

2

Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC : a drug-drug interaction study

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Ma, Y. | Chen, Q. | Zhang, Y. | +11

3

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD) : a prospective, single-arm, multicenter, phase IV study

enthalten in: BMC medicine | 2023

von Li, J. | Qin, S. | Wen, L. | +32

4

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer : The APPROVE Randomized Clinical Trial

enthalten in: JAMA oncology | 2022

von Wang, T. | Tang, J. | Yang, H. | +14

5

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02) : a single-arm, open-label, phase 2 trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Meng, X. | Wu, T. | Hong, Y. | +21

CommentIn: Lancet Gastroenterol Hepatol. 2022 Mar;7(3):200-201. - PMID 34998470

6

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer : The REALITY Randomized Clinical Trial

enthalten in: JAMA oncology | 2022

von Lin, Y. | Qin, S. | Li, Z. | +22

CommentIn: JAMA Oncol. 2022 Feb 1;8(2):250-251. - PMID 34913944

7

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC : The Phase III ACTIVE Study (CTONG1706)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Zhao, H. | Yao, W. | Min, X. | +23

CommentIn: J Thorac Oncol. 2021 Sep;16(9):1426-1428. - PMID 34425993

8

Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma

enthalten in: Annals of translational medicine | 2020

von Zheng, Y. | Wang, Z. | Yan, C. | +5

1
[1]